Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer

Genetic dynamics underlying cancer progression are largely unknown and several genes involved in highly prevalent illnesses (e.g., hypertension, obesity, and diabetes) strongly concur to cancer phenotype heterogeneity. To study genotype-phenotype relationships contributing to the mutational evolutio...

Full description

Bibliographic Details
Main Authors: Alessandro Ottaiano, Michele Caraglia, Annabella Di Mauro, Gerardo Botti, Angela Lombardi, Jerome Galon, Amalia Luce, Luigi D’Amore, Francesco Perri, Mariachiara Santorsola, Fabienne Hermitte, Giovanni Savarese, Fabiana Tatangelo, Vincenza Granata, Francesco Izzo, Andrea Belli, Stefania Scala, Paolo Delrio, Luisa Circelli, Guglielmo Nasti
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/10/3073
Description
Summary:Genetic dynamics underlying cancer progression are largely unknown and several genes involved in highly prevalent illnesses (e.g., hypertension, obesity, and diabetes) strongly concur to cancer phenotype heterogeneity. To study genotype-phenotype relationships contributing to the mutational evolution of colorectal cancer (CRC) with a focus on liver metastases, we performed genome profiling on tumor tissues of CRC patients with liver metastatic disease and no co-morbidities. We studied 523 cancer-related genes and tumor-immune microenvironment characteristics in primary and matched metastatic tissues. We observed a loss of <i>KRAS</i> and <i>SMAD4</i> alterations and a high granzyme-B+ T-cell infiltration when the disease did not progress. Conversely, gain in <i>KRAS</i>, <i>PIK3CA</i> and <i>SMAD4</i> alterations and scarce granzyme-B+ T-cells infiltration were observed when the tumor evolved towards a poly-metastatic spread. These findings provide novel insights into the identification of tumor oligo-metastatic status, indicating that some genes are on a boundary line between these two clinical settings (oligo- vs. poly-metastatic CRC). We speculate that the identification of these genes and modification of their evolution could be a new approach for anti-cancer therapeutic strategies.
ISSN:2072-6694